Key result
Visfatin acts as an inflammatory adipokine linked to obesity, atherosclerosis, endothelial dysfunction, and CHD.
Visfatin is an adipokine that plays a role in the development and progression of atherosclerotic lesions by promoting smooth muscle cell proliferation and angiogenesis.
May inform biomarker studies in obesity-related CHD; leaves open clinical utility pending higher-level evidence.
Coronary heart disease (CHD) is a generic designation for a group of related syndromes resulting from myocardial ischemia – an imbalance between cardiac blood supply (perfusion) and myocardial oxygen demand. Visfatin (VF) is a recently discovered adipokine with different functions, Visfatin is mainly found in visceral adipose tissue and mimics insulin in lowering plasma glucose levels and, Visfatin emerges as a player in the development and progression of atherosclerotic lesions by directly promoting smooth muscle cell proliferation, Aberrant angiogenesis is now considered a feature of the atherogenic process in both coronary and carotid diseases. This adipokine was previously known as a pre-B-cell colony-enhancing factor (PBEF) or Nicotinamide phosphoribosyltransferase (NAmPRTase or Nampt) an enzyme that in humans is encoded by the NAMPT gene and demonstrated to be an intracellular protein with a key enzyme role in nicotinamide adenine dinucleotide (NAD)
No takes yet. Share an insight, caveat, or question.
Al-Kraity et al. (2021) conducted a review in Coronary heart disease. Visfatin was evaluated. Visfatin is an adipokine that acts as an inflammatory marker related to obesity, atherosclerosis, endothelial dysfunction, and coronary heart disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: